Search Bar & Filters

Found 1 Actively Recruiting clinical trials

A

Actively Recruiting

Study Comparing Giredestrant Versus Fulvestrant, Both With a CDK4/6 Inhibitor, In Patients With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Prior Endocrine Therapy

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy.

Age: 18Years +All GendersPhase 3
351 locations
Salcaja Clinical Trials | DecenTrialz